JPAD-Journal of Prevention of Alzheimers Disease

Article	Citations
Erratum to: Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats	436
Informing etiological heterogeneity of mild cognitive impairment and risk for progression to dementia with plasma p-tau217	236
Ten Years after the National Alzheimer's Plan: Dementia Remains a Hidden Syndrome in France	227
Evaluation of Memantine in AAV-AD Rat: A Model of Late-Onset Alzheimer's Disease Predementia	207
Neuroprotective Effects of IVIG against Alzheimer's Disease via Regulation of Antigen Processing and Presentation by MHC Class I Molecules in 3xTg-AD Mice	98
Validation of the CogDrisk Instrument as Predictive of Dementia in Four General Community-Dwelling Populations	79
Maximizing the Utility of Alzheimer's Disease Trial Data: Sharing of Baseline A4 and LEARN Data	68
The Geras Solutions Cognitive Test for Assessing Cognitive Impairment: Normative Data from a Population-Based Cohort	50
Key considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation	48
On the 2024 Alzheimer's Association Criteria: Still Not Ready for Clinical Use	47
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease	43
‘Time Saved' As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings	38
Effects of Non-Invasive Brain Stimulation on Alzheimer's Disease	35
Informal care for people with dementia in Europe	33
Association between Comorbidity Indices and Functional Autonomy in Individuals with Cognitive Impairment: A Systematic Review	33
Disparities in out-of-pocket costs for disease-modifying therapy under Japan's universal health insurance system	32
Metformin in the Prevention of Alzheimer's Disease and Alzheimer's Disease Related Dementias	28
Phase 1 Studies of the Anti-Tau Monoclonal Antibody JNJ-63733657 in Healthy Participants and Participants with Alzheimer's Disease	24
Projected Savings to Canadian Provincial Budgets from Reduced Long-Term Care Home Utilization Due to a Disease-Modifying Alzheimer's Treatment	23
The Shape Trail Test Is Sensitive in Differentiating Older Adults with Mild Cognitive Impairment: A Culture-neutral Five-minute Test	23
Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer's Disease from Frontotemporal Lobar Degeneration	22
Introduction to the Special Issue on the A4 Study	20
Donanemab: Appropriate use recommendations	20
AMBAR: A Therapeutical Approach for Alzheimer's Disease Patients Regardless of Amyloid Status	20
Independent and Joint Associations of Socioeconomic Status and Lifestyle behaviors with Cognitive Impairment among Elderly Chinese Population	20

Brain health services for the secondary prevention of cognitive impairment and dementia: Opportunities, challenges, and the business case for existing and future facilities	19
LMTK2 and CRB1 are two novel risk genes for Alzheimer's disease in Han Chinese	19
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease	17
In Vivo Detection of Changes Related to Cortical Columnar Organization and Neuroinflammation Across the AD Continuum	16
Aducanumab: Appropriate Use Recommendations	16
Are Population-Level Approaches to Dementia Risk Reduction Under-Researched? A Rapid Review of the Dementia Prevention Literature	16
Longitudinal Evolution of Financial Capacity and Cerebral Tau and Amyloid Burden in Older Adults with Normal Cognition or Mild Cognitive Impairment	16
Novel Blood-Based Biomarkers and Disease Modifying Therapies for Alzheimer's Disease. Are We Ready for the New Era?	15
Global Burden of Dementia Death from 1990 to 2019, with Projections to 2050: An Analysis of 2019 Global Burden of Disease Study	15
Longitudinal Impacts of Precision Greenness on Alzheimer's Disease	14
Erratum to: Alzheimer's Disease Composite Score: a Post-Hoc Analysis Using Data from the LipiDiDiet Trial in Prodromal Alzheimer's Disease	13
Cardiovascular-kidney-metabolic syndrome and incidence of dementia among older adults	13
Can Virtual Scientific Conferences Facilitate Two-Way Learning between Dementia Researchers and Participants?	12
Erratum to: Education as Risk Factor of Mild Cognitive Impairment: The Link to the Gut Microbiome	12
Disease-Modifying Antirheumatic Drugs and Dementia Prevention: A Systematic Review of Observational Evidence in Rheumatoid Arthritis	12
Cardiovascular Risk Scales Association with Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cardiovascular Low Cardiovascular Risk Regions	12
The Therapeutic Effects of Noninvasive Brain Stimulation Combined with Cognitive Training in Elders with Alzheimer's Disease or Amnesic Mild Cognitive Impairment	12
Programmed Death of Microglia in Alzheimer's Disease: Autophagy, Ferroptosis, and Pyroptosis	12
The Causal Relationship between Genetically Predicted Biological Aging, Alzheimer's Disease and Cognitive Function: A Mendelian Randomisation Study	11
Validation of an Ultra-Sensitive Method for Quantitation of Phospho-Tau 217 (pTau217) in Human Plasma, Serum, and CSF using the ALZpath pTau217 Assay on the Quanterix HD-X Platform	11
Association of Vascular Endothelial Growth Factor Levels with Risk of Alzheimer's Disease: A Systematic Review and Meta-Analysis	11
Relationship between Plasma P-Tau217 and Amyloid PET in Racial and Ethnic Underrepresented Groups (RE-URG) Compared with Non RE-URG in LEARN and A4	11
16th Clinical Trials on Alzheimer's Disease (CTAD) Boston, MA (USA) October 24–27, 2023: Posters	11
Reproductive Markers in Alzheimer's Disease Progression: The Framingham Heart Study	10
Modulatory Effect of Blood LDL Cholesterol on the Association between Cerebral Aβ and Tau Deposition in Older Adults	10
Serum Tau-A and Tau-C Levels and Their Association with Cognitive Impairment and Dementia Progression in a Memory Clinic Derived Cohort	10
Where Do We Go from Here?	10
Reply to Letter to the Editor: “Early-Onset Type 2 Diabetes and Risk of Dementia”	10
Plasma amyloid-β precursor protein 669–711/amyloid-β1–42 ratio is associated with cognition in Alzheimer's disease	10
Effectiveness of Physical Exercise on Alzheimer's disease. A Systematic Review	10
Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy	10
Erratum to: Digital Clock Drawing as an Alzheimer's Disease Susceptibility Biomarker: Associations with Genetic Risk Score and APOE in Older Adults	10
Development of a Mobile-First Registry to Recruit Healthy Volunteers and Members of Underrepresented Communities for Alzheimer's Disease Prevention Studies	9
Association of Blood MicroRNA Expression and Polymorphisms with Cognitive and Biomarker Changes in Older Adults	9
Basal forebrain global functional connectivity is preserved in asymptomatic presenilin-1 E280A mutation carriers: Results from the Colombia cohort	9
A Cholecystokinin Analogue Ameliorates Cognitive Deficits and Regulates Mitochondrial Dynamics via the AMPK/Drp1 Pathway in APP/PS1 Mice	9
Associations of early-onset coronary heart disease and genetic susceptibility with incident dementia and white matter hyperintensity: A prospective cohort study	9
Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabece	9
Corrigendum to “17th Clinical Trials on Alzheimer's Disease (CTAD) Madrid, Spain, October 29 - November 1, 2024: Symposia, Oral Communications” [J Prev Alzheimers Dis 2025;12(1S):100043].	9
Data-Driven Thresholding Statistically Biases ATN Profiling across Cohort Datasets	9
Cardiovascular health, genetic predisposition, and dementia risk among atherosclerotic cardiovascular disease patients	8
Current Themes and Controversies in the Alzheimer's Disease Field: Looking Ahead to the CTAD Meeting in San Francisco, November 29–December 2 2022	8
Usefulness of Cerebrospinal Fluid Alzheimer's disease biomarkers in older patients: Evidence from a national multicenter prospective study	8
The Effects of Subjective Cognitive Decline on APOE Genotype Disclosure in the Butler Hospital Alzheimer's Prevention Registry	8
Representation of Racial and Ethnic Minority Populations in Dementia Prevention Trials: A Systematic Review	8
The ‘Aducanumab Story': Will the Last Chapter Spell the End of the ‘Amyloid Hypothesis' or Mark a New Beginning?	8
Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer's Disease	7
The Association between Sugar-Sweetened Beverages and Cognitive Function in Middle-Aged and Older People: A Meta-Analysis	7
Chinese Preclinical Alzheimer's Disease Study (C-PAS): Design and Challenge from PET Acceptance	7
The Association between Peanut and Peanut Butter Consumption and Cognitive Function among Community-Dwelling Older Adults	7

Feasibility and acceptability of remote APOE-genotyping among research volunteers of an online recruitment registry (The Dutch Brain Research Registry)	7
The Clinical Trials Alzheimer's Disease (CTAD) Meeting in San Francisco, Fall 2022, Will Be a Very Exciting Event!	7
Bacillus Calmette-Guerin (BCG) Vaccine Impact on Dementia Risk in Bladder Cancer Patients: A Systematic Review and Meta-Analysis	7
Feasibility of computerized motor, cognitive and speech tests in the home: Analysis of TAS Test in 2,300 older adults	7
Brain photobiomodulation: a potential treatment in Alzheimer’s and Parkinson’s diseases	7
Mechanisms Underlying Non-Pharmacological Dementia Prevention Strategies: A Translational Perspective	7
The Scottish Brain Health Service Model: Rationale and Scientific Basis for a National Care Pathway of Brain Health Services in Scotland	7
Major Cost Drivers in Assessing the Economic Burden of Alzheimer's Disease: A Structured, Rapid Review	7
Interest in and Experience with Genetic Testing for Late-Onset Medical Conditions: Results from the National Poll on Healthy Aging	7
17th Clinical Trials on Alzheimer's Disease (CTAD) Madrid, Spain, October 29 - November 1, 2024	7
Multiomics Blood-Based Biomarkers Predict Alzheimer's Predementia with High Specificity in a Multicentric Cohort Study	7
“Back to Braak”: Role of Nucleus Reuniens and Subcortical Pathways in Alzheimer's Disease Progression	7
Diagnostic Accuracy of Plasma p-tau217 for Detecting Pathological Cerebrospinal Fluid Changes in Cognitively Unimpaired Subjects Using the Lumipulse Platform	6
Determinants of Medical Direct Costs of Care among Patients of a Memory Center	6
Platform Trials to Expedite Drug Development in Alzheimer's Disease: A Report from the EU/US CTAD Task Force	6
Association of Preeclampsia with Incident Dementia and Alzheimer's Disease among Women in the Framingham Offspring Study	6
First Experiences with Amyloid-Related Imaging Abnormalities — Yet without Imaging that Can Rule Out Cerebral Injury or Monitor Efficacy of Recommended Management	6
Clinical Meaningfulness in Alzheimer's Disease Clinical Trials. A Report from the EU-US CTAD Task Force	6
The Cost-Effectiveness of Three Prevention Strategies in Alzheimer's Disease: Results from the Multidomain Alzheimer Preventive Trial (MAPT)	6
Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats	6
Fingolimod ameliorates amyloid deposition and neurodegeneration in APP/PS1 mouse model of Alzheimer's disease	6
Consistency between Treatment Effects on Clinical and Brain Atrophy Outcomes in Alzheimer's Disease Trials	6
Relationships of Hypnotics with Incident Dementia and Alzheimer's Disease: A Longitudinal Study and Meta-Analysis	6
Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer's Treatments with Different Duration and Route of Administration	6
Association of Multi-Domain Factors with Cognition in the UK Biobank Study	6
Posters	6
Patient eligibility for amyloid-targeting immunotherapies in Alzheimer's disease	6
Tackling a Major Deficiency of Diversity in Alzheimer's Disease Therapeutic Trials: An CTAD Task Force Report	6
A Statistical Framework for Assessing the Relationship between Biomarkers and Clinical Endpoints in Alzheimer's Disease	6
Universal Prevention of Dementia in Italy: A Document Analysis of the 21 Italian Regional Prevention Plans	6
Symposia — Oral Communications — Late Breaking News	6
The Future is Now: Advancing Blood-Based Markers	5
Flavonoid-Rich Fruit Intake in Midlife and Late-Life and Associations with Risk of Dementia: The Framingham Heart Study	5
Left Frontoparietal Control Network Connectivity Moderates the Effect of Amyloid on Cognitive Decline in Preclinical Alzheimer's Disease: The A4 Study	5
Prevention of Alzheimer's Disease and Cognitive Decline with Diet & Lifestyle: Proceedings of the A. G. Leventis Foundation Conference	5
Aducanumab: Appropriate Use Recommendations	5
Unveiling Potential Biomarkers in Cerebrospinal Fluid for Amyloid Pathological Positivity in Non-Demented Individuals	5
The role of serum vitamins in mediating the effect of neurodegenerative diseases on subcortical brain volume	5
How Will Aducanumab Approval Impact AD Research?	5
Embryo Selection for a Carrier of an Early-Onset Alzheimer's Disease-Associated Mutation in the PSEN1 Gene	5
Exploring the Association between Amyloid-β and Memory Markers for Alzheimer's Disease in Cognitively Unimpaired Older Adults	5
Decreased Gray—White Matter Contrast of [11C]-PiB Uptake in Cognitively Unimpaired Subjects with Severe Obstructive Sleep Apnea	5
«Compounded Interest» in Alzheimer's Disease: Do New Amyloid-Targeting Treatments Justify Their Use	5
The Dawn of a New Era of Alzheimer's Research and Drug Development	5
Latent cognitive profiles and their associations with instrumental activities of daily living among older adults without dementia: A United States national cross-sectional study	5
Peripheral Blood BRCA1 Methylation Positively Correlates with Major Alzheimer's Disease Risk Factors	5
Public Policy Should Foster Alzheimer's Treatment Availability: Comment on the Draft US Medicare Decision to Limit Payment for Aducanumab (Aduhelm™) to Patients Participating in Clinical Trials	5
Reducing the Effects of Ageing on Cognition with Therapeutic Intervention of an Oral Multi-Nutrient: The REACTION Pilot Trial Study Design	5
Visual Event-Related Potentials under External Emotional Stimuli as Early Signs for Mild Cognitive Impairment	5
Higher Cognitive Reserve Is Beneficial for Cognitive Performance Via Various Locus Coeruleus Functional Pathways in the Pre-Dementia Stage of Alzheimer's Disease	5
A Fay-Herriot Model for Estimating Subjective Cognitive Decline among Military Veterans	5
Alzheimer's Disease Biomarker Decision-Making among Patients with Mild Cognitive Impairment and Their Care Partners	5
Environmental Distractions during Unsupervised Remote Digital Cognitive Assessment	5
At a Glance: An Update on Neuroimaging and Retinal Imaging in Alzheimer's Disease and Related Research	4
Microglial activation states and their implications for Alzheimer's Disease	4
Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies	4
High Intake of Dietary Cholesterol Decreases the Risk of All-Cause Dementia and AD Dementia: A Results from Framingham Offspring Cohort	4
ASURE Clinical Trial Protocol: A Randomized, Placebo-Controlled, Proof-of-Concept Study Aiming to Evaluate Safety and Target Engagement following Administration of TW001 in Early Alzheimer's Disease P	4
Anti-Hypertensive Drugs Moderate the Relationship of Blood Pressure with Alzheimer's Pathologies and Neurodegenerative Markers in Non-Demented Hypertensive Older Adults	4
Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial	4
Baseline habitual dietary nitrate intake and Alzheimer's Disease related neuroimaging biomarkers in the Australian Imaging, Biomarkers and Lifestyle study of ageing	4
Lifestyle factors and plasma biomarkers of Alzheimer's disease: A narrative review	4
Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021	4
Preventing dementia in Italy: Estimations of modifiable risk factors and public health implications	4
Assessing the causal role of lipid metabolites in Alzheimer's disease: A mendelian randomization study	4
Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer's and Parkinson's Patients	4
Early-Onset Type 2 Diabetes and Risk of Dementia	4
China Initiative for Multi-Domain Intervention (CHINA-IN-MUDI) to Prevent Cognitive Decline: Study Design and Progress	4
Implications of Emerging Uses of Genetic Testing for Alzheimer's Disease	4
A Conformational Variant of p53 (U-p53AZ) as Blood-Based Biomarker for the Prediction of the Onset of Symptomatic Alzheimer's Disease	4
Everyday Functioning and Entorhinal and Inferior Temporal Tau Burden in Cognitively Normal Older Adults	4
Economic Impact of Progression from Mild Cognitive Impairment to Alzheimer Disease in the United States	4
Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylat	4
Reply to: Mitochondrial dysfunction as the missing link between circadian syndrome and dementia	4
Associations and Potential Multiple Mechanisms between Subjective Hearing Loss and Cognitive Impairment	4
Phase 1/2a Intravenous and Subcutaneous Oligomer-Specific Antibody KHK6640 in Mild to Moderate Alzheimer's Disease	4
Motor abilities and cognitive performance in Latinos with autosomal dominant Alzheimer's disease	4
Current status and future directions for the diagnosis and management of mild cognitive impairment in Southeast Asia: A SEACURE consensus paper	4
Opposite causal effects of type 2 diabetes and metformin on Alzheimer's disease	4
Associations of ischemic heart disease with brain glymphatic MRI indices and risk of Alzheimer's disease	4

A Hierarchical Bayesian Latent Class Model for the Diagnostic Performance of Mini-Mental State Examination and Montreal Cognitive Assessment in Screening Mild Cognitive Impairment Due to Alzheimer's D	3
Continuous Associations between Remote Self-Administered Cognitive Measures and Imaging Biomarkers of Alzheimer's Disease	3
Semorinemab Pharmacokinetics and The Effect on Plasma Total Tau Pharmacodynamics in Clinical Studies	3
Magnetic Resonance Imaging-Negative Cerebral Amyloid Angiopathy: Cerebrospinal Fluid Amyloid-β42 over Amyloid Positron Emission Tomography	3
Hypnotics and Incident Dementia: A Risk Assessment	3
Dietary Cholesterol and Dementia Risk	3
Corrigendum to “Multiomics Blood-Based Biomarkers Predict Alzheimer's Predementia with High Specificity in a Multicentric Cohort Study” [The Journal of Prevention of Alzheimer's Disease 2024;11(3):567	3
Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer's Disease	3
Mendelian Randomization Analysis Reveals Causal Factors behind Alzheimer's Disease Risk: Evidence, Opportunities, and Challenges	3
The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report	3
15th Conference Clinical Trials Alzheimer's Disease, November 29- December 2, 2022, San Francisco, CA, USA: Symposia - Oral Communications - Late Breaking Abstracts (Clinical Trial Alzheimer's Disease	3
Corrigendum to Enhancing dementia prediction: A 19-year validation of the CAIDE risk score with insulin resistance and APOE ε4 integration in a population-based cohort	3
Update to: Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease	3
Multimorbidity and risk of dementia: A systematic review and meta-analysis of longitudinal cohort studies	3
Sample size estimates for biomarker-based outcome measures in clinical trials in autosomal dominant Alzheimer's disease	3
Effects of Vitamin D3 Combined with Folic Acid on Domain and Specific Cognitive Function among Patients with Mild Cognitive Impairment: A Randomized Clinical Trial	3
The Room Where It Happens: Clinician Reflections on Returning Preclinical Alzheimer's Biomarker Results to Research Participants	3
Expectancy Does Not Predict 18-month Treatment Outcomes with Cognitive Training in Mild Cognitive Impairment	3
Genetic predisposition to high circulating levels of interleukin 6 and risk for Alzheimer's disease. Discovery and replication	3
Multi-omics analysis of druggable genes to facilitate Alzheimer's disease therapy: A multi-cohort machine learning study	3
Alzheimer's Disease Prevention Health Coaching	3
The Effects of Dual-Task Training on Cognitive and Physical Functions in Older Adults with Cognitive Impairment; A Systematic Review and Meta-Analysis	3
Editorial Board	3
Predictive Utility of Plasma Amyloid and Tau for Cognitive Decline in Cognitively Normal Adults	3
Cytomegalovirus Infection and Alzheimer's Disease: A Meta-Analysis	3
Association of the difference between cystatin C- and creatinine-based estimated glomerular filtration rate with cerebral small vessel disease: A large prospective cohort study	3
Therapeutic Targets for Alzheimer's Disease: Amyloid Vs. Non-Amyloid. Where Does Consensus Lie Today? An CTAD Task Force Report	3
Mendelian Randomization Analysis to Assess Whether Magnetic Resonance Imaging Signs of Cerebral Small Vessel Disease Can Cause Cognitive Decline and Dementia	3
Eligibility for donanemab trial in a population-based study of cognitive aging	3
Heightened Prevalence of Common Hospital-Treated Infections Preceding Dementia Diagnosis with Accelerated Dementia Onset after Influenza	3
Development and Concurrent Validity of the Short-Form CogDrisk Dementia Risk Assessment Tool	3
A Japanese Multicenter Study on PET and Other Biomarkers for Subjects with Potential Preclinical and Prodromal Alzheimer's Disease	3
Adult Renal Dysfunction and Risk of Dementia or Cognitive Decline: Brain-Kidney Axis Hypothesis Based on a Systematic Review and Meta-Analysis	3
Association between Family Household Income and Cognitive Resilience among Older US Adults: A Cross-Sectional Study	3
Baseline Findings of PreventE4: A Double-Blind Placebo Controlled Clinical Trial Testing High Dose DHA in APOE4 Carriers before the Onset of Dementia	3
Unsupervised Performance of the CogState Brief Battery in the Brain Health Registry: Implications for Detecting Cognitive Decline	3
Burden of Illness in People with Alzheimer's Disease: A Systematic Review of Epidemiology, Comorbidities and Mortality	3
Who Benefited the Most? Effectiveness of a Lifestyle Intervention Against Cognitive Decline in Older Women and Men – Secondary Analysis of the AgeWell.de-trial	3
Effects of Folic Acid and Vitamin B12 Supplementation on Cognitive Impairment and Inflammation in Patients with Alzheimer's Disease: A Randomized, Single-Blinded, Placebo-Controlled Trial	3
Association between Resting Heart Rate and Machine Learning-Based Brain Age in Middle- and Older-Age	3
Mitochondrial dysfunction as the missing link between circadian syndrome and dementia	3
The Role of Thyroid Dysfunction in Alzheimer's Disease: A Systematic Review and Meta-Analysis	3
Appropriate Use Recommendations for Lecanemab	3
Meta Analysis of the Correlation between Periodontal Health and Cognitive Impairment in the Older Population	3
Gender-Specific Design and Effectiveness of Non-Pharmacological Interventions against Cognitive Decline — Systematic Review and Meta-Analysis of Randomized Controlled Trials	3
Adjudicating Mild Cognitive Impairment Due to Alzheimer's Disease as a Novel Endpoint Event in the TOMMORROW Prevention Clinical Trial	3
“Time Saved” Calculations to Improve Decision-Making in Progressive Disease Studies	3
Cutting through the noise: A narrative review of Alzheimer's disease plasma biomarkers for routine clinical use	2
A Large Retrospective Cohort Study on the Risk of Alzheimer's Disease and Related Dementias in Association with Vascular Diseases and Cancer Therapy in Men with Prostate Cancer	2
Geroscience and Alzheimer's Disease Drug Development	2
Quantifying Recruitment Source and Participant Communication Preferences for Alzheimer's Disease Prevention Research	2
Blood-brain barrier integrity disruption is associated with both chronic vascular risk factors and white matter hyperintensities	2
What Is Reasonable and Necessary for Alzheimer Patients from Randomized Clinical Trials to Clinical Practice?	2
Using Digital Tools to Advance Alzheimer's Drug Trials During a Pandemic: The EU/US CTAD Task Force	2
Alzheimer's Disease Prediction Using Fly-Optimized Densely Connected Convolution Neural Networks Based on MRI Images	2
Item-Level Investigation of Participant and Study Partner Report on the Cognitive Function Index from the A4 Study Screening Data	2
Protocol of a Phase II Randomized, Multi-Center, Double-Blind, Placebo-Controlled Trial of S-Adenosyl Methionine in Participants with Mild Cognitive Impairment or Dementia Due to Alzheimer's Disease	2
Microstructural white matter injury contributes to cognitive decline: Besides amyloid and tau	2
Leveraging Diverse Regulated Cell Death Patterns to Identify Diagnosis Biomarkers for Alzheimer's Disease	2
Is “Pre-Preclinical AD” Helpful to the EU/US CTAD Task Force?	2
Pharmacological Inventions for Alzheimer Treatment in the United States of America: A Revision Patent from 2010–2020	2
Safety, Tolerability and Pharmacokinetics of Icapamespib, a Selective Epichaperome Inhibitor, in Healthy Adults	2
China Alzheimer's Disease and Neurodegenerative Disorder Research (CANDOR) -A Prospective Cohort Study for Alzheimer's Disease and Vascular Cognitive Impairment	2
Performance of Plasma Biomarkers Combined with Structural MRI to Identify Candidate Participants for Alzheimer's Disease-Modifying Therapy	2
Alzheimer's Disease Linkage to Real-World Evidence (AD-LINE) Study: Linking Claims Data to Phase 3 GRADUATE Study of Gantenerumab	2
Validation of the multi-day Boston remote assessment of neurocognitive health (BRANCH) among cognitively impaired & unimpaired older adults	2
Association between 9p21–23 Locus and Frailty in a Community-Dwelling Greek Population: Results from the Hellenic Longitudinal Investigation of Ageing and Diet	2
Dual Task Performance Is Associated with Amyloidosis in Cognitively Healthy Adults	2
Editorial Board	2
Hearing loss, diet, and cognitive decline: interconnections for dementia prevention	2
Adding the Topographical Information from Tau-PET to the A/T/(N) Framework: Steps Towards Staging AD in Vivo	2
Influence of APOE ε4 on performance of CSF biomarkers in differentiating clinical Alzheimer's disease	2
Plasma neurofilament light mediates the effects of Apolipoprotein E on brain atrophy and cognitive decline in the comorbid Alzheimer's disease and cerebral small vessel disease	2
Association between Longitudinal Cerebrospinal Fluid Alzheimer's Biomarkers and the Lifestyle for Brain Health (LIBRA) Index: Findings from the European Prevention of Alzheimer's Dementia Cohort Study	2
Content	2
A Genetic Validation of the Neurodegeneration Biomarkers Tau-A and Tau-C - A Mendelian Randomization Study	2
Examining the Role of Community Engagement in Enhancing the Participation of Racial and Ethnic Minoritized Communities in Alzheimer's Disease Clinical Trials; A Rapid Review	2
Clusters of Dementia Literacy: Implications from a Survey of Older Adults	2
Diversifying Recruitment Registries: Considering Neighborhood Health Metrics	2
Sustainable Participation in Community Health Programs to Promote a Healthy Lifestyle and Prevent and Protect against Dementia among Rural Taiwanese Middle-Aged and Older Adults	2
Fructose Consumption is Associated with a Higher Risk of Dementia and Alzheimer's Disease: A Prospective Cohort Study	2
The role of Aβ in Alzheimer's Disease as an Evolutionary Outcome of Optimized Innate Immune Defense	2
Distinct CSF α-synuclein aggregation profiles associated with Alzheimer's disease phenotypes and MCI-to-AD conversion	2
Are We There Yet (and How Do We Get There…)?	2
Tau Pathologies Mediate the Associations of Vascular Risk Burden with Cognitive Impairments in Non-demented Elders: The CABLE Study	2
What Matters to Patients with Alzheimer's Disease and Their Care Partners? Implications for Understanding the Value of Future Interventions	2
At-home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact	2
Prediction of Alzheimer's Disease Based on 3D Genome Selected circRNA	2
The AlzMatch Pilot Study - Feasibility of Remote Blood Collection of Plasma Biomarkers for Preclinical Alzheimer's Disease Trials	2
MemScreen: A smartphone application for detection of mild cognitive impairment: A validation study	2
The impact of hypertension prevention and modification on dementia burden: A systematic review of economic studies	2
Association between Neuropsychological Performance and CSF Profile in Subjective Cognitive Decline: Towards the Diagnosis of Preclinical AD	2
Association between Cognitive Reserve Indicator and Chronic Disease-Free Survival: A Large Community-Based Longitudinal Study	2
Exploring the Associations between Alzheimer's Disease and GBM Mediated by Microglia Based on Network Analysis	2
Increased Incident Alzheimer's Disease among Individuals with Varicose Veins: A Population-Based Cohort Study	2